Compare IHD & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | IHD | IXHL |
|---|---|---|
| Founded | 2011 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.6M | 134.7M |
| IPO Year | N/A | N/A |
| Metric | IHD | IXHL |
|---|---|---|
| Price | $6.93 | $0.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.7K | ★ 6.9M |
| Earning Date | 01-01-0001 | 02-13-2026 |
| Dividend Yield | ★ 10.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.49 | $0.08 |
| 52 Week High | $5.47 | $2.25 |
| Indicator | IHD | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 78.98 | 38.59 |
| Support Level | $6.45 | $0.34 |
| Resistance Level | $6.87 | $0.37 |
| Average True Range (ATR) | 0.09 | 0.02 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 92.93 | 8.24 |
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.